prime medicine(US:PRME) ZACKS·2025-11-07 14:11Core Insights - Prime Medicine, Inc. reported a quarterly loss of $0.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.28, representing an earnings surprise of -14.29% [1] - The company generated revenues of $1.23 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 75.35%, compared to revenues of $0.21 million a year ago [2] - The stock has increased approximately 43.2% since the beginning of the year, outperforming the S&P 500's gain of 14.3% [3] Financial Performance - Over the last four quarters, Prime Medicine has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $8.95 million, and for the current fiscal year, it is -$1.25 on revenues of $7.63 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Prime Medicine belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] Future Outlook - The sustainability of Prime Medicine's stock price movement will largely depend on management's commentary during the earnings call and the subsequent revisions of earnings estimates [3][4] - The estimate revisions trend for Prime Medicine was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]